scholarly journals Assessment of Platelet Reactivity and Inflammatory Markers in Coronary Artery Bypass Graft Patients Treated with Acetylsalicylic Acid with Flavonoid Supplementation

Molecules ◽  
2021 ◽  
Vol 26 (24) ◽  
pp. 7486
Author(s):  
Aldona Siennicka ◽  
Magdalena Kłysz ◽  
Monika Adamska ◽  
Kornel Chełstowski ◽  
Andrzej Biskupski ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Acetylsalicylic Acid ◽  
Coronary Artery Bypass ◽  
Postoperative Period ◽  
Inflammatory Markers ◽  
Platelet Reactivity ◽  
Artery Bypass ◽  
Late Phase ◽  
Bypass Graft ◽  
Aggregation Effect

The recommended pharmacological therapy for patients with coronary artery disease (CAD) treated by coronary artery bypass grafting (CABG) is acetylsalicylic acid (ASA). To improve the antiplatelet effect, supplementation with flavonoids is also recommended. The aim of this study was to estimate anti-aggregation properties of diosmin, in combination with ASA, pre- and postoperatively and assess the relationship of this therapy with inflammatory processes in CAD patients undergoing CABG. The study patients (n = 26) took diosmin (1000 mg/day); the control patients (n = 27) took a placebo. The therapeutic period for taking diosmin was from at least 30 days before to 30 days after CABG. All patients also took 75 mg/day ASA. Platelet aggregation and IL-6, CRP, and fibrinogen concentrations were determined before and 30 days after surgery. Results showed that diosmin did not enhance the anti-aggregation effect of ASA at any assessment time. However, there was a stronger anti-aggregation effect 30 days after surgery that was diosmin independent and was associated with acute-phase markers in the postoperative period. Increased levels of inflammatory markers in the late phase of the postoperative period may provide an unfavorable prognostic factor in long-term follow-up, which should prompt the use of stronger antiplatelet therapy in patients after CABG.

IMMUNE FUNCTION IN THE EARLY POSTOPERATIVE PERIOD PREDICTS OUTCOME IN CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY

1990 ◽  
Vol 18 (Supplement) ◽  
pp. S252
Author(s):  
Marcus P. Haw ◽  
Gregory T. Steltzer ◽  
Emma J. Lewis ◽  
Bradley C. Borlase ◽  
Lynda Kabbash ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Graft ◽  
Immune Function ◽  
Coronary Artery Bypass ◽  
Postoperative Period ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Early Postoperative Period ◽  
Artery Bypass Graft ◽  
Cabg Surgery

scholarly journals Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Sammer Diab ◽  
Mattan Arazi ◽  
Leonid Sternik ◽  
Ehud Raanani ◽  
Erez Kachel ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Acetylsalicylic Acid ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Red Blood Cell Transfusion ◽  
Bleeding Complications ◽  
Perioperative Outcomes ◽  
Chest Drainage ◽  
Group A

Abstract Background Management of patients treated with Ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis. The aim of the study was to compare bleeding complications in patients treated with ticagrelor combined with acetylsalicylic acid (ASA) versus ASA alone until 1 day before surgery. Methods Bleeding complications, defined as the composite of red blood cell transfusion ≥1000 ml, chest drainage ≥2000 ml, and bleeding requiring surgical re-exploration, were compared in 161 patients, with 101 on preoperative acetylsalicylic acid (ASA) alone (group A) and 65 on ticagrelor + ASA (group B). Results There were no differences in bleeding complications between the two groups (26% vs. 27% in group A and B, respectively), with similar chest drainage in the first 24 h (569 ± 393 ml and 649 ± 427 ml, respectively). Conclusions Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that continued management with ticagrelor until surgery may be safe.

Platelet Reactivity Unit in Predicting Risk of Bleeding in Patients Undergoing Coronary Artery Bypass Graft Surgery

2016 ◽  
Vol 23 (6) ◽  
pp. e1537-e1541 ◽  
Author(s):  
Zaid Altheeb ◽  
Ahmad Sbitan ◽  
Martin Shabiah ◽  
Vincent Debari ◽  
Aiman Hamdan ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Graft ◽  
Coronary Artery Bypass ◽  
Platelet Reactivity ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Artery Bypass Graft ◽  
Risk Of Bleeding
Sign in / Sign up

Export Citation Format

Share Document